Barclays PLC Raises Stock Position in Alto Neuroscience, Inc. (NYSE:ANRO)

Barclays PLC increased its holdings in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 872.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 29,599 shares of the company’s stock after purchasing an additional 26,556 shares during the period. Barclays PLC owned 0.11% of Alto Neuroscience worth $339,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in Alto Neuroscience by 148.7% during the 3rd quarter. Geode Capital Management LLC now owns 469,988 shares of the company’s stock worth $5,378,000 after acquiring an additional 281,018 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Alto Neuroscience during the third quarter valued at approximately $124,000. Wellington Management Group LLP acquired a new position in shares of Alto Neuroscience during the third quarter worth $694,000. State Street Corp grew its holdings in Alto Neuroscience by 123.7% during the 3rd quarter. State Street Corp now owns 236,857 shares of the company’s stock valued at $2,710,000 after purchasing an additional 130,985 shares in the last quarter. Finally, Philadelphia Financial Management of San Francisco LLC increased its stake in Alto Neuroscience by 1.5% during the 3rd quarter. Philadelphia Financial Management of San Francisco LLC now owns 449,952 shares of the company’s stock worth $5,147,000 after buying an additional 6,663 shares during the period.

Analyst Ratings Changes

ANRO has been the subject of a number of analyst reports. Robert W. Baird reduced their price target on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Stifel Nicolaus cut their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Rodman & Renshaw lowered Alto Neuroscience from a “buy” rating to a “neutral” rating in a report on Wednesday, October 23rd. RODMAN&RENSHAW lowered Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Finally, Wedbush cut Alto Neuroscience from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $29.00 to $4.00 in a research note on Wednesday, October 23rd. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Alto Neuroscience Trading Up 3.7 %

ANRO stock opened at $4.60 on Monday. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. The firm’s 50-day simple moving average is $4.24 and its 200 day simple moving average is $8.72. Alto Neuroscience, Inc. has a fifty-two week low of $3.56 and a fifty-two week high of $24.00.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.05. Analysts predict that Alto Neuroscience, Inc. will post -2.54 EPS for the current year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.